Research Projects Page

Since our inception as an outcome committee in 2015, we have consistently and considerably expanded our ability to produce rigorous outcomes research. In 2018, we established a more formal program and leadership, including full time outcomes research staff. The result of these allocated resources has been a productive output across multiple specialty disease states. Below are highlighted outcomes from studies completed in recent years.

Research Project List

Research categories (field_research_categories)
Research categories (field_research_categories)
111-115 of 115 results

Retreatment of Genotype 1 Hepatitis C Virus with Sofosbuvir, Simeprevir, and Ribavirin Following Treatment Failure with an NS5A-Containing Direct-Acting Antiviral Regiment

Prior to the release of sofosbuvir/velpatasvir/voxilaprevir, few options for retreating patients failing HCV direct acting antiviral (DAA) therapy. This study evaluated the effectiveness of sofosbuvir + simeprevir + ribavirin for 24 weeks in retreating patients who previously failed HCV treatment containing an NS5A inhibitor.

An Interdisciplinary Team Approach to Hepatitis C Evaluation and Treatment: Assessing the Impact of Clinical Pharmacist Involvement on HCV Clinical Practice and Treatment

This study demonstrated the benefits of pharmacist integration into an interdisciplinary to treatment patients with chronic HCV. Pharmacist integration resulted in improved patient engagement, reduced provider burden, and increased rate of HCV treatment.

Assessing the Impact of High Touch Specialty Pharmacy Services in Patients Receiving Teriparatide

This study found that patients utilizing VSP services were 62% more likely to complete teriparatide treatment and 49% less likely to drop out of treatment after completing 12 months of teriparatide compared to non-VSP patients. Additionally, the majority of patients (64%) required the use of the Vanderbilt Medication Assistance Program (MAP) to complete teriparatide treatment, a program only available to VSP patients.

Hepatitis C Treatment in HIV Coinfection: Approaches, Challenges, and Future Opportunities

While historical treatments combining interferon and ribavirin were less efficacious in HIV/HCV coinfection, modern direct-acting antiviral (DAA) therapies have shown similar clinical efficacy in HIV/HCV coinfection as in HCV monoinfection. In light of these findings, HIV/HCVcoinfected patients may benefit even more from new HCV treatment approaches. This article reviews the many therapeutic options for HIV/HCV coinfected patients with emphasis on avoiding drug-drug interactions.

Real World Assessment of All-Oral, Sofosbuvir-Based, Hepatitis C Therapy at an Academic Medical Center with Integrated Specialty Pharmacy Services

This study was among the first to evaluate patient outcomes to all-oral, sofosbuvir (SOF)-based, HCV therapies in a real world setting and assess the impact of a clinic-integrated specialty pharmacy on therapy completion. We found higher completion rates in patients filling through VSP (97%) compared to outside pharmacies (93%), and a 100% medication access rate.